JPRN-jRCT2080222700未知2 期
A Phase II Trial of R435(Bevacizumab) in stage IVB, persistent or recurrent carcinoma of the cervix
适应症
试验速览
- 阶段
- 2 期
- 入组人数
- 6
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- Female
入选标准
- •Adult patients, >=20 years of age.
- •- GOG Performance Status of 0 or 1.
- •- Primary stage IVB, persistent or recurrent carcinoma of the cervix which is not amenable to curative treatment.
排除标准
- •- Previously treated with chemotherapy except when used concurrently with radiation therapy.
- •- Serious non-healing wound, ulcer, or bone fracture. This includes history of abdominal fistula, gastrointestinal perforation or intra-abdominal abscess within 6 months must pass before study entry.
- •- History or evidence upon physical examination of CNS disease.
- •- History of hemoptysis(>=Grade2) within 1 month before study entry.
研究者
相似试验
未知
2 期
Phase II clinical study of R435 (bevacizumab) in combination with paclitaxel in patients with inoperable metastatic breast cancerInoperable metastatic breast cancerJPRN-jRCT2080220385Chugai Pharmaceutical Co., Ltd.
未知
1 期
Phase I/II study of R435 (Bevacizumab) in patients with metastatic colorectal cancerMetastatic colorectal cancerJPRN-jRCT2080220022Chugai Pharmaceutical Co., Ltd.
进行中（未招募）
不适用
A phase II trial assessing bevacizumab in the treatment of advanced or metastatic angiosarcomapatients with advanced or metastatic angiosarcomaEUCTR2004-004546-41-FIHelsinki University Central Hospital10
未知
3 期
A study of R435 (Bevacizumab) in Combination With R340 (Capecitabine) and Cisplatin in Patients With Advanced Gastric Cancer.Gastric CancerJPRN-jRCT2080220416Chugai Pharmaceutical Co., Ltd.
未知
3 期
A compassionate use study of R435(Bevacizumab) in chemotherapy naive and inoperable malignant pleural mesothelioma patientschemotherapy naive and inoperable malignant pleural mesotheliomaJPRN-jRCT2080223406CHUGAI PHARMACEUTICAL CO., LTD.12